Healthcare Industry News: influenza
News Release - February 8, 2006
Aethlon Medical Announces Avian Flu Treatment ApplicationSAN DIEGO--(HSMN NewsFeed)--Feb. 8, 2006--Aethlon Medical, Inc., (OTCBB:AEMD ), a pioneer in developing therapeutic devices for infectious disease, announced today that it is expanding the applications of its Hemopurifier(TM) treatment technology to include the H5N1 strain of the Avian Flu Virus. The rapid progression of H5N1 infection allows only a brief treatment window with antiviral drugs. The Hemopurifier will target the direct capture of H5N1 and modulation of the immune response as a means to treat when drugs are ineffective or unavailable. In order to advance the H5N1 treatment application, Aethlon will manufacture and ship the treatment devices to established influenza researchers who will seek to establish the benefits of the Hemopurifier as a treatment against Avian Flu.
The application of the Hemopurifier to treat Avian Flu is based on evolving research that indicates a primary cause of death in H5N1 infection is the release of inflammatory cells and chemicals known as a "Cytokine Storm." As a result of cytokine storm, the immune system is hyper-activated to the extent that the normal immune response of clearing viruses, toxins, and infected cells becomes overshadowed by the destruction of healthy red blood cells. Antiviral drugs are not able to shut off a cytokine storm once it has been triggered. Thus, those individuals with robust immune systems are actually at greater risk than the immune compromised individuals who are most susceptible to regular seasonal flu strains. The hyper-activation of the immune system as a result of cytokine storm also fueled the Spanish Flu Pandemic of 1918. That pandemic is credited with killing between 20-50 million individuals in eighteen months.
The Hemopurifier offers the potential to provide the dual benefit of clearing H5N1 and modulating the overproduction of cytokines. The Hemopurifier is based on hemofiltration principals already indicated as a treatment for sepsis and shock caused by cytokine overproduction. In addition, the Hemopurifier design provides a mechanism to separate H5N1 from circulation so that it can be captured by immobilized affinity agents that bind to glycoproteins on the surface of the virus. Therefore, the Hemopurifier combines the potential to tame the immune system without destroying natural defenses, with the ability to reduce the body burden of infectious H5N1 virus.
About Aethlon Medical
Aethlon Medical is developing the first medical device to treat infectious disease. The device, known as the Hemopurifier(TM), is a broad-spectrum treatment countermeasure against drug and vaccine resistant bioweapons, naturally evolving pandemic threats, and chronic infectious disease targets such as Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). More information on Aethlon Medical and the Hemopurifier(TM) technology can be found at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Source: Aethlon Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.